China Biologic Products (NASDAQ:CBPO) PT Set at $105.00 by Deutsche Bank

China Biologic Products (NASDAQ:CBPO) has been assigned a $105.00 target price by research analysts at Deutsche Bank in a research report issued on Friday, March 2nd. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank’s target price points to a potential upside of 29.63% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the company. Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a research report on Wednesday, November 15th. BidaskClub upgraded China Biologic Products from a “strong sell” rating to a “sell” rating in a report on Tuesday, February 13th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $101.00.

How to Become a New Pot Stock Millionaire

Shares of China Biologic Products (CBPO) traded down $1.54 on Friday, reaching $81.00. The company’s stock had a trading volume of 210,612 shares, compared to its average volume of 225,593. China Biologic Products has a 12 month low of $71.85 and a 12 month high of $120.46. The firm has a market cap of $2,683.76, a P/E ratio of 34.04, a P/E/G ratio of 1.23 and a beta of 1.62.

China Biologic Products (NASDAQ:CBPO) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.90 EPS for the quarter, beating the Zacks’ consensus estimate of $0.89 by $0.01. China Biologic Products had a return on equity of 21.30% and a net margin of 18.34%. The firm had revenue of $90.10 million for the quarter, compared to analysts’ expectations of $85.15 million. During the same period last year, the firm earned $0.95 EPS. The company’s quarterly revenue was up 16.1% on a year-over-year basis. equities research analysts anticipate that China Biologic Products will post 5.22 EPS for the current year.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CBPO. SG Americas Securities LLC purchased a new position in China Biologic Products in the 4th quarter worth approximately $117,000. Legal & General Group Plc lifted its stake in China Biologic Products by 41.2% in the 3rd quarter. Legal & General Group Plc now owns 2,966 shares of the biopharmaceutical company’s stock worth $274,000 after purchasing an additional 865 shares in the last quarter. Cubist Systematic Strategies LLC lifted its stake in China Biologic Products by 73.2% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 4,617 shares of the biopharmaceutical company’s stock worth $426,000 after purchasing an additional 1,952 shares in the last quarter. State of New Jersey Common Pension Fund D purchased a new position in China Biologic Products in the 3rd quarter worth approximately $439,000. Finally, Landscape Capital Management L.L.C. lifted its stake in China Biologic Products by 27.7% in the 4th quarter. Landscape Capital Management L.L.C. now owns 7,254 shares of the biopharmaceutical company’s stock worth $571,000 after purchasing an additional 1,573 shares in the last quarter. 56.27% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “China Biologic Products (NASDAQ:CBPO) PT Set at $105.00 by Deutsche Bank” was reported by BBNS and is owned by of BBNS. If you are viewing this piece of content on another publication, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/03/27/china-biologic-products-cbpo-pt-set-at-105-00-by-deutsche-bank/1962934.html.

About China Biologic Products

China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL
Ohtani Goes Deep in Third Straight Game for Angels
Ohtani Goes Deep in Third Straight Game for Angels


Leave a Reply

 
© 2006-2018 BBNS.